Tranexamic acid

Generic Name: Tranexamic acid

Brand Names: Cyklokapron, Lysteda

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₅NO_₂

CAS Number: 1197-18-8

Unique Ingredient Identifier: 6T84R30KC1

Background: Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.

It was first patented in 1957 and received its initial US approval in 1986.

Indication: Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...

Associated Conditions: Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)

Associated Therapies: -

Clinical Trials

Can Tranexamic Acid Reduce Bleeding After Post Partum Hemorrhage in Cesarean Section Delivery

Phase 4

Completed

Conditions: Post Partum Hemorrhage

Interventions: Drug: saline serum
Drug: Tranexamic Acid

First Posted Date: 2012-05-16

Last Posted Date: 2012-05-22

Lead Sponsor: Hédi Chaker Hospital

Target Recruit Count: 74

Registration Number: NCT01599468

Locations: 🇹🇳
Hedi Chaker University Hospital of Sfax, Department of Anesthesiology and Intensive Care, Sfax, Tunisia

Tranexamic Acid in On-pump CABG With Premature Clopidogrel Cessation

Not Applicable

Completed

Conditions: Coronary Artery Bypass Graft
Coronary Artery Disease

Interventions: Drug: Saline
Drug: Tranexamic Acid

First Posted Date: 2012-05-11

Last Posted Date: 2012-05-11

Lead Sponsor: Li Lihuan

Target Recruit Count: 120

Registration Number: NCT01596738

Locations: 🇨🇳
Cardiovascular Institute and Fuwai Hospital, Beijing, China

Tranexamic Acid for Unilateral Total Knee Arthroplasty

Phase 3

Completed

Conditions: Blood Loss

Interventions: Drug: Tranexamic Acid
Other: haemostasia

First Posted Date: 2012-05-09

Last Posted Date: 2012-12-19

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 150

Registration Number: NCT01594671

Locations: 🇪🇸
Hospital de la Esperanza, Barcelona, Spain
🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?

Not Applicable

Terminated

Conditions: Hip Fracture
Anemia

Interventions: Drug: Tranexamic Acid
Drug: Placebo

First Posted Date: 2012-02-20

Last Posted Date: 2015-02-05

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 72

Registration Number: NCT01535781

Locations: 🇩🇰
Hvidovre Hospital, Hvidovre, Copenhagen, Denmark

Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery

Phase 2

Terminated

Conditions: Bleeding

Interventions: Drug: MDCO 1
Drug: MDCO 2
Drug: MDCO 3
Drug: MDCO 4
Drug: Saline
Drug: Tranexamic Acid

First Posted Date: 2012-02-09

Last Posted Date: 2015-12-10

Lead Sponsor: The Medicines Company

Target Recruit Count: 44

Registration Number: NCT01530399

Locations: 🇩🇪
Charité Berlin, Berlin, Germany
🇩🇪
Universitätsklinikum Bonn, Bonn, Germany
🇩🇪
Universität Leipzig - Herzzentrum, Leipzig, Germany

and more 2 locations

Epsilon Aminocaproic Acid Vs. Tranexamic Acid Vs. Placebo for Prevention of Blood Loss in Total Knee Arthroplasty

Not Applicable

Conditions: Osteoarthritis

Interventions: Drug: Normal Saline
Drug: Epsilon Aminocaproic Acid
Drug: Tranexamic Acid

First Posted Date: 2012-02-07

Last Posted Date: 2016-07-26

Lead Sponsor: Heekin Orthopedic Research Institute

Target Recruit Count: 54

Registration Number: NCT01527968

Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Tranexamic Acid
Drug: normal saline

First Posted Date: 2012-01-26

Last Posted Date: 2013-07-02

Lead Sponsor: University of Saskatchewan

Target Recruit Count: 44

Registration Number: NCT01519245

The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis

Phase 3

Conditions: Hemoptisis

Interventions: Drug: tranexamic acid

First Posted Date: 2011-12-21

Last Posted Date: 2015-04-14

Lead Sponsor: Meir Medical Center

Target Recruit Count: 100

Registration Number: NCT01496196

Locations: 🇮🇱
Pulmonary department, Meir Medical Center, Kfar Saba, Israel

Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT

Not Applicable

Completed

Conditions: Osteoarthritis of Knee

Interventions: Other: Drain clamping and tranexamic acid
Other: No clamp and placebo
Procedure: Drain clamping
Drug: Tranexamic acid

First Posted Date: 2011-10-10

Last Posted Date: 2011-11-06

Lead Sponsor: Mahidol University

Target Recruit Count: 240

Registration Number: NCT01449552

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Phase 2

Completed

Conditions: Telangiectasia, Hereditary Hemorrhagic
Epistaxis

Interventions: Drug: Sterile saline
Drug: Estriol
Drug: Bevacizumab
Drug: Tranexamic Acid

First Posted Date: 2011-08-02

Last Posted Date: 2018-10-19

Lead Sponsor: James Gossage

Target Recruit Count: 123

Registration Number: NCT01408030

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Georgia Regents University, Augusta, Georgia, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy